Skip to content
Operation Infinite Justice – Lifestyle
Author:
Tarsus Pharmaceuticals, Inc
Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
April 29, 2026
Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease
March 31, 2026
TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus
March 23, 2026
←
Previous Page
1
2